<DOC>
	<DOCNO>NCT00308945</DOCNO>
	<brief_summary>Vasoactivity topical drug may prognostic relevance glaucoma . There little information major class , prostaglandin analogue regard aspect . The purpose study compare effect travoprost 0.004 % latanoprost 0.005 % choroidal blood flow retinal vascular diameter glaucoma patient . After washout current topical medication , intraocular pressure ( IOP ) eye ( Goldmann applanation tonometry ) , choroidal blood flow ( laser Doppler flowmetry ) retinal vessel diameter ( Retinal Vessel Analyzer ) one randomly select eye measure baseline , two week 4 week treatment travoprost latanoprost QD , randomize , double mask 2-way cross-over study 20 open angle glaucoma patient .</brief_summary>
	<brief_title>Influence Prostaglandins Ocular Blood Flow Glaucoma Patients</brief_title>
	<detailed_description>Background Glaucoma lead cause blindness worldwide . Chronic primary open-angle glaucoma common form among Caucasian patient . The key feature glaucoma damage optic nerve head , necessarily related increase intraocular pressure ( IOP ) . The actual therapeutic armamentarium glaucoma include miotic , beta-blockers , alpha-adrenergic agonist , oral topical carbonic anhydrase inhibitor , prostaglandin analogue , latter late addition armamentarium potent topical IOP lower drug . Besides IOP , ocular blood flow alteration incriminate glaucoma . Hence , relevance assess effect anti-glaucomatous drug ocular blood flow . Rationale study Vasoactivity topical drug may prognostic relevance glaucoma . There little information major class , prostaglandin analogue regard aspect . The vascular activity two prostaglandin analogue , travoprost 0.004 % latanoprost 0.005 % , already Swiss market , test . Study objectives Primary Objective : To assess effect two prostaglandin analogue , travoprost 0.004 % latanoprost 0.005 % choroidal blood flow primary open-angle glaucoma patient . Secondary Objective : To assess effect travoprost 0.004 % latanoprost 0.005 % retinal vascular diameter primary open-angle glaucoma patient . Investigational plan Primary open-angle-glaucoma patient assess regard inclusion/exclusion criterion . After washout current topical medication ( beta-blockers prostaglandin analogue : 4 week ; topical carbonic anhydrase inhibitor alpha-agonists : 2 week ; Pilocarpine : 1 week ) , half patient ( 17 patient ) treat travoprost 0.004 % 1 month 17 patient treat latanoprost 0.005 % duration . Efficacy safety variable assess baseline , 2 week , 1 month treatment . After first period , patient wash 4 week baseline efficacy safety parameter obtain . Afterwards , patient treat compound . Again , efficacy safety variable assess 2 week 1 month treatment . Design Single center , randomize , double mask 2-way cross-over design . Randomization The patient divide two group , group alternatively start either travoprost 0.004 % latanoprost 0.005 % . Recruitment management carry study nurse mask baseline blood flow measurement result . Masking randomization procedure entrust Alcon PHARMACEUTICAL AG . The drug product study prepared following procedure : Each product label independent labeling operation . For study four different product label : travatan medicin A , travatan medicin B , xalatan medicin A xalatan medicin B . Each label operation start end line clearance procedure label order 100 % inspected person independent person label . On label patient number indicate . The label order initiate use randomization list indicate product label patient . The randomization sequence pull uniform distribution arbitrary seed ( Randomization Performed SAS 8.2 NT use RANUNI [ seed ] ) . During independent labeling operation also disclosure label provide patient number indicate open label . After release independent labeling procedure , assembly package two carton box assembly carton box start patient . The assembly box also also label patient number/investigator number protocol number . Release label sample always do independent QA department .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>Patients fulfil two three follow criterion one eye : ) typical glaucomatous disc , b ) visual field damage ( cluster three point ( except rim point ) least one hemifield reduce 5 dB great include least one point reduce 10 dB great ; cluster two point reduce 10 dB great ; three adjacent point nasal horizontal meridian differ 5 dB great mirror point opposite side meridian ) , c ) intraocular pressure 21 mm Hg least one occasion washout . No closed iridocorneal angle , evidence secondary glaucoma , pseudoexfoliation , pigmentary dispersion , form retinal neuroophthalmologic disease could result visual field defect . No history drug alcohol abuse . Best correct visual acuity worse 2/10 either eye &lt; 0.2 Snellen . Inadequate transparency ocular medium define physical examination . Severe central field loss define sensitivity &lt; 10dB least 2 4 visual field test point closest point fixation . Any abnormality physician 's view would prevent reliable applanation tonometry LDF eye , include ametropia &gt; 3 dpt . History chronic recurrent severe inflammatory eye disease scleritis uveitis . History ocular trauma intraocular surgery within past 6 month . History infection inflammation within past 3 month . History clinically significant progressive retinal disease retinal degeneration , diabetic retinopathy retinal detachment . A known hypersensitivity compound test . Need concomitant medication may interfere evaluation ocular blood flow . Variability &gt; 30 % Laser Doppler Flowmetry ( sample 6 measurement ) eye . Pregnancy , breastfeeding , woman childbearing age without adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Blood flow</keyword>
	<keyword>Choroid</keyword>
	<keyword>Retina</keyword>
	<keyword>Prostaglandin analogue</keyword>
</DOC>